oxazoles has been researched along with 4-(2-(2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)-4-isoxazolyl)methoxy)phenyl)cyclopropyl)benzoic acid in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Al-Khaifi, A; Angelin, B; Rudling, M | 1 |
| Deng, Q; Feng, S; Li, J; Pan, G; Wu, Z; Yang, W; Zhang, T | 1 |
1 trial(s) available for oxazoles and 4-(2-(2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)-4-isoxazolyl)methoxy)phenyl)cyclopropyl)benzoic acid
| Article | Year |
|---|---|
An FXR Agonist Reduces Bile Acid Synthesis Independently of Increases in FGF19 in Healthy Volunteers.
Topics: Administration, Oral; Bile Acids and Salts; Cholestenones; Cholesterol 7-alpha-Hydroxylase; Dose-Response Relationship, Drug; Down-Regulation; Fibroblast Growth Factors; Gastrointestinal Agents; Healthy Volunteers; Humans; Liver; Male; Oxazoles; Receptors, Cytoplasmic and Nuclear; Signal Transduction; Time Factors | 2018 |
1 other study(ies) available for oxazoles and 4-(2-(2-chloro-4-((5-cyclopropyl-3-(2,6-dichlorophenyl)-4-isoxazolyl)methoxy)phenyl)cyclopropyl)benzoic acid
| Article | Year |
|---|---|
Farnesoid X receptor (FXR) agonists induce hepatocellular apoptosis and impair hepatic functions via FXR/SHP pathway.
Topics: Animals; Apoptosis; Chenodeoxycholic Acid; Liver Neoplasms, Experimental; Mice; Oxazoles; Phosphatidylinositol 3-Kinases; Receptors, Cytoplasmic and Nuclear; Signal Transduction | 2022 |